Serum p53 Antibodies and Survival in Small-Cell Lung Cancer
Author Information
Author(s): Murray P V, Soussi T, O'Brien M E R, Smith I E, Brossault S, Norton A, Ashley S, Tavassoli M
Primary Institution: The Royal Marsden Hospital
Hypothesis
Do serum p53 antibodies predict survival in small-cell lung cancer?
Conclusion
The presence of high levels of p53 antibodies is associated with a survival advantage in small-cell lung cancer patients.
Supporting Evidence
- 54 patients were positive for p53 antibodies, representing 23% of the cohort.
- The study is the largest homogenous group examining p53 antibodies in small-cell lung cancer.
- A high titre of p53 antibodies is associated with a relative risk of death of 1.71.
Takeaway
This study found that patients with small-cell lung cancer who have certain antibodies in their blood may live longer than those who do not.
Methodology
The study tested serum samples for p53 antibodies using a standardized ELISA technique and correlated results with patient survival.
Participant Demographics
231 patients (63% male, median age 65) diagnosed and treated for SCLC.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI: 1.14–2.58
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website